•	Other serious medical conditions or diseases that in the opinion of the enrolling investigator would make the patient inappropriate for the study
•	Any other condition that in the opinion of the enrolling investigator would make the patient inappropriate for the study

Dosing Information
Belinostat is administered orally twice daily on Days 1-14 of each 21-day cycle. Ribociclib is administered orally once daily continuously. Dose modifications for belinostat and ribociclib are described below.
Belinostat Dose Modifications
Belinostat dose reductions are based on the worst grade of adverse events (AEs) experienced during the previous cycle.
Belinostat Dose Reduction Guidelines
If the patient experiences a Grade ≥ 3 AE, the dose of belinostat is reduced to 100 mg PO BID until recovery to Grade ≤ 2. Once recovered to Grade ≤ 2, the dose of belinostat is increased back to 200 mg PO BID. If the patient experiences a